Yes — HRT preserves bone density and reduces fracture risk, and the evidence for this is strong. The more useful questions are who it suits, what happens to your bones when you stop, and how it compares with dedicated bone treatments. For women going through menopause early, HRT is often the single most important intervention for long-term skeletal health.
- HRT reduces fractures — the Women’s Health Initiative showed roughly a third fewer hip and vertebral fractures
- It is the treatment of choice for bone protection in early menopause and premature ovarian insufficiency
- Bone protection lasts while you take it — density declines again after stopping, though some benefit persists
- The risk picture changed after the initial WHI reporting; for most women under 60 starting near menopause, benefits outweigh risks
- HRT is not usually first-line for treating established osteoporosis in women well past menopause
- Bone protection alone is rarely the sole reason to start HRT — but it is a significant factor in the decision
Few areas of women’s health have been as confused by headlines as HRT. The bone question deserves a clear answer, because the skeletal consequences of untreated early menopause are substantial and often overlooked in discussions dominated by hot flushes and cancer risk. Understanding where HRT sits alongside other osteoporosis treatments makes the decision considerably easier.
Why oestrogen matters to bone
Oestrogen restrains the osteoclasts — the cells that break down old bone. When oestrogen falls at menopause, that brake is released and bone resorption accelerates sharply. Women typically lose bone density fastest in the first five to seven years after their final period, sometimes losing up to 20% of their bone mass during this window.
This is why menopause is the single biggest driver of osteoporosis in women, and why the timing of menopause matters so much. A woman whose periods stop at 42 faces roughly a decade of additional oestrogen deficiency compared with one who reaches menopause at 52 — and that decade shows up in her bone density.
What the evidence actually shows
The Women’s Health Initiative remains the largest randomised trial of HRT, and on the bone question its findings were unambiguous and positive. Women taking combined oestrogen and progestogen had approximately 33% fewer hip fractures and a similar reduction in vertebral fractures compared with placebo. Notably, this fracture reduction occurred across the whole study population — including women who were not selected for having low bone density in the first place, which is unusual among bone treatments.
Bone mineral density gains on HRT are typically in the range of 3–6% at the spine over the first few years, with smaller gains at the hip. This places HRT broadly in the same territory as bisphosphonates for density preservation, though the two are used in quite different clinical situations.
Who benefits most from HRT for bone protection
HRT is most clearly indicated for bone health in the following groups:
- Premature ovarian insufficiency (menopause before 40) — here HRT is considered replacement of a hormone that should still be present, not an optional extra, and is generally recommended until at least the natural age of menopause
- Early menopause (before 45), whether natural or following surgery, chemotherapy or radiotherapy
- Women under 60, within 10 years of menopause, who also have menopausal symptoms and low bone density or elevated fracture risk
- Women who cannot tolerate bisphosphonates and remain within the appropriate age window
Our guide to early menopause and fracture prevention covers the first two groups in more depth.
What happens to your bones when you stop HRT
This is the part most often left out of the conversation. Bone protection from HRT is largely contingent on continuing to take it. After stopping, bone loss resumes — and in the first year or two it can be relatively rapid, in some cases approaching the rate seen immediately after menopause itself.
Some residual fracture protection does appear to persist for a period after discontinuation, but it is not permanent. For women who stop HRT and remain at elevated fracture risk, a planned transition — often to a bisphosphonate — is worth discussing rather than simply stopping and hoping. This is a scenario where a specialist review before stopping is genuinely valuable.
HRT compared with dedicated bone treatments
The comparison depends heavily on age and clinical context:
- HRT — treats menopausal symptoms and protects bone simultaneously. Best suited to women near menopause, particularly those with early menopause. Protection is contingent on continued use
- Bisphosphonates — the standard first-line treatment for established postmenopausal osteoporosis, with a long safety record and residual benefit after stopping. See our guide to bisphosphonate side effects
- Denosumab — effective, but requires strict dosing continuity because of rebound bone loss if stopped without transition
- Anabolic treatments — reserved for very high fracture risk, building new bone rather than slowing loss
For a 70-year-old with established osteoporosis, HRT is rarely the right answer. For a 46-year-old with premature menopause and falling bone density, it frequently is.
Weighing the risks honestly
The initial WHI reporting in 2002 produced a sharp global decline in HRT prescribing, much of which is now regarded as an overcorrection. Subsequent reanalysis established that risk varies considerably with age at initiation, time since menopause, type of preparation and route of administration.
In broad terms: for women starting HRT under 60 and within 10 years of menopause, the balance of benefit to risk is generally favourable. Transdermal oestrogen (patches or gel) avoids the small increase in venous thrombosis risk associated with oral preparations. Breast cancer risk is associated mainly with combined oestrogen-progestogen preparations and increases with duration of use — the absolute increase is small but real, and deserves a proper individual discussion rather than either dismissal or alarm.
Women who have had a hysterectomy take oestrogen alone, which carries a more favourable risk profile than combined therapy.
The women we see who have been most let down are those who went through menopause in their early forties and were never told what that meant for their bones. Symptoms were treated, or not treated, and the skeletal consequences simply went undiscussed until a DEXA scan fifteen years later delivered unwelcome news. If you had an early menopause, the bone conversation should have happened then — and if it did not, it should happen now. Equally, HRT is not a bone drug in isolation, and we would rarely start it purely for density in a woman a long way past menopause. The right answer depends on your age, your fracture risk, your symptoms and your own view of the trade-offs. That is a conversation worth having properly — book an assessment and we will work through it within a structured care pathway alongside your GP or menopause specialist.
Frequently Asked Questions
Can HRT be prescribed specifically to prevent osteoporosis?
Yes, particularly for women with premature ovarian insufficiency or early menopause, where bone protection is a primary indication. For women closer to the typical age of menopause, HRT is more often prescribed for symptoms with bone protection as a significant additional benefit. In women well past menopause, dedicated bone treatments are usually preferred.
Is HRT as effective as bisphosphonates for bone?
For preserving bone density and reducing fracture risk while being taken, HRT performs comparably. The key differences are that bisphosphonates retain residual benefit for a period after stopping, have a longer track record specifically in osteoporosis treatment, and are appropriate across a much wider age range.
How long can I stay on HRT for bone protection?
For premature ovarian insufficiency, generally until at least the average age of natural menopause, around 51. Beyond that there is no arbitrary cut-off — continuation is reviewed periodically, weighing symptom benefit, bone protection and individual risk factors. The older idea that HRT must be stopped after five years is no longer considered good practice.
Will my bone density fall if I stop HRT?
Yes, bone loss resumes after stopping and can be relatively rapid in the first year or two. If you are at elevated fracture risk, it is worth discussing a planned transition to another bone treatment rather than stopping without a follow-on plan, and arranging a DEXA scan to establish where you stand.
Does testosterone or body-identical HRT make a difference to bone?
Oestrogen is the component that does the bone work. Body-identical oestradiol delivered transdermally is widely used and effective for bone. Testosterone in women is prescribed principally for low sexual desire rather than bone protection, and is not a substitute for oestrogen where skeletal health is the concern.
Medically reviewed by Dr. Taher Mahmud, Consultant Rheumatologist and Co-Founder, London Osteoporosis Clinic. Dr. Mahmud has over 25 years of clinical experience in bone health and osteoporosis management.
This article is for informational purposes only and does not constitute medical advice. Decisions about starting, continuing or stopping hormone replacement therapy should always be made with a qualified clinician who knows your full medical history.
References:
[1] Cauley JA, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA, 2003. PubMed
[2] Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny, 2014. PubMed
[3] NICE. Menopause: diagnosis and management (NG23). nice.org.uk
[4] NHS. Hormone replacement therapy (HRT) — Benefits and risks. NHS.uk
